Fig. 5From: Association of the Advanced Lung Cancer Inflammation Index (ALI) and Gustave Roussy Immune (GRIm) score with immune checkpoint inhibitor efficacy in patients with gastrointestinal and lung cancer(A) Forest plots of the relationship between Gustave Roussy Immune Score and progression-free survival (I2 = 23.6%, p = 0.269; HR: 1.78, 95% CI: 1.35–2.34, p < 0.001). (B) Sensitivity analysis of the association between the Gustave Roussy Immune Score and progression-free survival. HR, hazard ratio; CL, confidence intervalBack to article page